|
Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) Valoración de DCF
CN | Healthcare | Medical - Diagnostics & Research | HKSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) Bundle
¡Explore las perspectivas financieras de Hangzhou Tigermed Consulting Co., Ltd. (3347HK) con nuestra calculadora DCF fácil de usar! Ingrese sus proyecciones para el crecimiento, los márgenes y los gastos para calcular el valor intrínseco de Hangzhou Tigermed Consulting Co., Ltd. (3347HK) y refinar su enfoque de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,993.7 | 3,409.1 | 5,567.6 | 7,566.6 | 7,885.5 | 10,198.1 | 13,189.0 | 17,057.1 | 22,059.6 | 28,529.2 |
| Revenue Growth, % | 0 | 13.88 | 63.32 | 35.91 | 4.21 | 29.33 | 29.33 | 29.33 | 29.33 | 29.33 |
| EBITDA | 1,252.5 | 1,353.2 | 2,251.1 | 2,587.1 | 3,112.0 | 3,989.9 | 5,160.1 | 6,673.4 | 8,630.6 | 11,161.7 |
| EBITDA, % | 41.84 | 39.69 | 40.43 | 34.19 | 39.47 | 39.12 | 39.12 | 39.12 | 39.12 | 39.12 |
| Depreciation | 46.2 | 154.6 | 201.8 | 282.7 | 326.4 | 358.5 | 463.7 | 599.6 | 775.5 | 1,002.9 |
| Depreciation, % | 1.54 | 4.53 | 3.62 | 3.74 | 4.14 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 |
| EBIT | 1,206.3 | 1,198.6 | 2,049.4 | 2,304.3 | 2,785.6 | 3,631.4 | 4,696.4 | 6,073.8 | 7,855.1 | 10,158.8 |
| EBIT, % | 40.29 | 35.16 | 36.81 | 30.45 | 35.33 | 35.61 | 35.61 | 35.61 | 35.61 | 35.61 |
| Total Cash | 2,181.0 | 10,839.2 | 9,155.8 | 8,418.4 | 7,968.9 | 9,644.4 | 12,472.9 | 16,131.0 | 20,861.9 | 26,980.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,242.9 | 1,410.1 | 2,244.2 | 3,237.0 | 3,871.5 | 4,386.5 | 5,673.0 | 7,336.7 | 9,488.5 | 12,271.2 |
| Account Receivables, % | 41.52 | 41.36 | 40.31 | 42.78 | 49.1 | 43.01 | 43.01 | 43.01 | 43.01 | 43.01 |
| Inventories | 1.3 | 5.0 | 6.5 | 23.7 | 25.0 | 19.1 | 24.7 | 32.0 | 41.4 | 53.5 |
| Inventories, % | 0.0430066 | 0.1479 | 0.11691 | 0.31338 | 0.31687 | 0.18761 | 0.18761 | 0.18761 | 0.18761 | 0.18761 |
| Accounts Payable | 80.3 | 108.2 | 157.9 | 168.7 | 266.2 | 291.6 | 377.1 | 487.7 | 630.8 | 815.8 |
| Accounts Payable, % | 2.68 | 3.17 | 2.84 | 2.23 | 3.38 | 2.86 | 2.86 | 2.86 | 2.86 | 2.86 |
| Capital Expenditure | -109.9 | -167.1 | -393.7 | -479.1 | -335.1 | -534.9 | -691.7 | -894.6 | -1,157.0 | -1,496.3 |
| Capital Expenditure, % | -3.67 | -4.9 | -7.07 | -6.33 | -4.25 | -5.24 | -5.24 | -5.24 | -5.24 | -5.24 |
| Tax Rate, % | 18.63 | 18.63 | 18.63 | 18.63 | 18.63 | 18.63 | 18.63 | 18.63 | 18.63 | 18.63 |
| EBITAT | 932.1 | 945.3 | 1,598.6 | 1,788.4 | 2,266.5 | 2,855.2 | 3,692.5 | 4,775.5 | 6,176.0 | 7,987.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -295.4 | 789.7 | 620.8 | 592.9 | 1,719.6 | 2,195.1 | 2,257.9 | 2,920.1 | 3,776.4 | 4,884.0 |
| WACC, % | 8.19 | 8.2 | 8.2 | 8.19 | 8.21 | 8.2 | 8.2 | 8.2 | 8.2 | 8.2 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 12,312.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 4,982 | |||||||||
| Terminal Value | 80,380 | |||||||||
| Present Terminal Value | 54,207 | |||||||||
| Enterprise Value | 66,519 | |||||||||
| Net Debt | -4,905 | |||||||||
| Equity Value | 71,424 | |||||||||
| Diluted Shares Outstanding, MM | 865 | |||||||||
| Equity Value Per Share | 82.58 |
What You Will Receive
- Authentic Hangzhou Tigermed Financials: Comprehensive historical and projected data for precise valuation.
- Customizable Inputs: Adjust parameters such as WACC, tax rates, revenue growth, and capital expenditures.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess the future performance of Hangzhou Tigermed.
- User-Friendly Design: Crafted for industry professionals while remaining approachable for newcomers.
Essential Features
- Customizable Forecast Inputs: Adjust vital parameters such as revenue growth, EBITDA %, and capital investments.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and other essential metrics.
- High-Precision Accuracy: Relies on real-world financial data from Hangzhou Tigermed Consulting Co., Ltd. for credible valuation results.
- Simplified Scenario Analysis: Effortlessly examine various assumptions and evaluate different outcomes.
- Efficiency Booster: Streamline the process by avoiding the need to create intricate valuation models from the ground up.
How It Functions
- Download: Obtain the ready-to-use Excel sheet featuring Hangzhou Tigermed Consulting Co., Ltd.'s (3347HK) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA percentage, and WACC to suit your analysis.
- Update Automatically: Benefit from real-time updates on intrinsic value and NPV calculations.
- Test Scenarios: Generate various projections and instantly compare the results.
- Make Decisions: Utilize the valuation outcomes to inform your investment strategy for Hangzhou Tigermed Consulting Co., Ltd. (3347HK).
Why Select Hangzhou Tigermed Consulting Co., Ltd. (3347HK)?
- Time-Saving: Skip the hassle of developing complex models – our solutions are ready to implement.
- Enhanced Accuracy: Access to dependable financial data and methodologies minimizes valuation discrepancies.
- Fully Customizable: Adjust the model to align with your specific assumptions and forecasts.
- User-Friendly Insights: Intuitive charts and outputs simplify data interpretation.
- Endorsed by Professionals: Crafted for industry experts who prioritize precision and functionality.
Who Should Benefit from Tigermed's Services?
- Pharmaceutical Investors: Make well-informed decisions regarding investments in Hangzhou Tigermed Consulting Co., Ltd. (3347HK).
- Market Analysts: Enhance evaluation processes with comprehensive market analysis tools.
- Consultants: Provide clients with expert insights into the healthcare consulting landscape swiftly and accurately.
- Business Executives: Gain insights into the valuation of major players like Tigermed to shape your business strategies.
- Students in Finance and Healthcare: Explore valuation methods using current data and real-case studies.
Contents of the Template
- Preloaded HANGZHOU TIGERMED Data: Historical and forecasted financial figures, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-quality sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Cells highlighted in yellow for adjusting revenue growth rates, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financials for in-depth analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios for performance evaluation.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.